Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis | Zendy

Thelma E. Tupasi | Zendy; Rajesh Gupta | Zendy; Manfred Danilovitš | Zendy; Andra Cīrule | Zendy; Epifanio Sànchez-Garavito | Zendy; Heping Xiao | Zendy; José Luis Cabrera | Zendy; Dante E. Vargas-Vasquez | Zendy; Mengqiu Gao | Zendy; Mohamed Awad | Zendy; Leesa M Gentry | Zendy; Lawrence Geiter | Zendy; Charles D. Wells | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis

Author(s) -

Thelma E. Tupasi,

Rajesh Gupta,

Manfred Danilovitš,

Andra Cīrule,

Epifanio Sànchez-Garavito,

Heping Xiao,

José Luis Cabrera,

Dante E. Vargas-Vasquez,

Mengqiu Gao,

Mohamed Awad,

Leesa M Gentry,

Lawrence Geiter,

Charles D. Wells

Publication year - 2015

Publication title -

bulletin of the world health organization

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.459

H-Index - 168

eISSN - 1564-0604

pISSN - 0042-9686

DOI - 10.2471/blt.15.154997

Subject(s) - tuberculosis , medicine , clinical trial , multiple drug resistance , intensive care medicine , drug resistance , biology , pathology , microbiology and biotechnology

New drugs for infectious diseases often need to be evaluated in low-resource settings. While people working in such settings often provide high-quality care and perform operational research activities, they generally have less experience in conducting clinical trials designed for drug approval by stringent regulatory authorities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research